Multiple target antigen stimulating cell therapy - HengRui YuanZheng Biotechnology

Drug Profile

Multiple target antigen stimulating cell therapy - HengRui YuanZheng Biotechnology

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator HengRui YuanZheng Bio-Technology
  • Class Cell therapies; Dendritic cell vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Solid tumours

Most Recent Events

  • 06 Sep 2016 Clinical trials in Solid tumours in China (IV) before September 2016
  • 06 Sep 2016 HengRui YuanZheng Bio-Technology plans a phase I/II trial for Solid tumours in China (NCT02858232)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top